Valorisation of regenerative innovations

To bring innovations from the laboratory to patient application very specific knowledge and expertise is needed. That knowledge, to create both economical and societal impact, is called valorization. To ensure this process takes place, public-private collaborations are essential.

Leiden Regenerative Medicine Platform

Leiden Regenerative Medicine Platform brings new medicines closer to the patient by commercialising innovative regenerative medicine therapies, diagnostics and technologies in order to accelerate breakthroughs in regenerative medicine across a broad range of diseases. Founded in 2016 by the LUMC, Leiden Regenerative Medicine Platform has attracted funding to support the commercialisation of its existing pipeline of regenerative medicine technologies.

Leiden Regenerative Medicine Platform works with academic projects from the earliest stages, with proprietary access to intellectual property developed at LUMC and strong networks throughout Europe, connecting scientific innovation in regenerative medicine to capital in order to maximise societal and commercial potential.

Alongside the development of a pipeline of regenerative therapies, Leiden Regenerative Medicine Platform provides access to its research expertise and world-class cGMP facilities through collaborations with partners worldwide.

Leiden BioScience Park

The LUMC is part of the Leiden BioScience Park (LBSP). At the park, several companies are located that develop and commercialise activities relevant to regenerative medicine. Research and development is focused on real-life application and intermediary components essential for regenerative therapies. The LUMC is part of public-private consortia together with new and existing companies at the park to drive innovations forward.

Center for Commercialisation of Regenerative Medicine

At an international level, we closely collaborate with the Canadian initiative the Center for Commercialisation of Regenerative Medicine (CCRM). CCRM focuses on commercializing living therapies. We at LUMC have the ambition to become the European hub of CCRM, ensuring access for the whole of Europe to the CCRM hub system, giving the opportunity to tap into niche expertise and techniques around the world. Currently CCRM has esthablished a hub in Australia and hubs in Japan and Israel are on the way.

‘Europe in danger of being out-innovated in regenerative medicine’

‘Europe in danger of being out-innovated in regenerative medicine’

According to Ton Rabelink, professor of internal medicine and head of nephrology at the LUMC in an interview with Horizon, the EU Magazine for Research & Innovation.